Wren Laboratories35 NE Industrial Road, Branford, Connecticut, USAYale University School of Medicine310 Cedar St, New Haven, Connecticut, USA
Wren Laboratories35 NE Industrial Road, Branford, Connecticut, USAYale University School of Medicine310 Cedar St, New Haven, Connecticut, USA.
Endocr Connect. 2014 Dec;3(4):215-23. doi: 10.1530/EC-14-0100. Epub 2014 Oct 14.
A critical requirement in neuroendocrine tumor (NET) management is a blood biomarker test that is sensitive, specific and reproducible. We evaluated a PCR-based 51-transcript signature to detect tumors, compared it with chromogranin A (CgA) and examined the confounding effect of proton pump inhibitors (PPIs), which cause falsely elevated CgA levels. The multigene signature was evaluated in two groups. Group 1: 125 prospectively collected NETs: gastroenteropancreatic NETs (n=91, including 42 pancreatic and 40 small intestinal), carcinoids of unknown primary (n=18) and other sites (n=16). Group 2: prospectively collected non-NET patients receiving PPIs (>1 month; dyspepsia, n=19; GERD, n=6; and pancreatitis, n=4) and 50 controls. All samples were analyzed by PCR (marker genes) and ELISA (DAKO-CgA). Sensitivity comparisons included χ(2), non-parametric measurements, and receiver operating characteristic (ROC) curves. Group 1: 123 NETs were PCR-positive (98.4%) compared with 50 (40%) CgA-positive (χ(2)=97.3, P<10(-26)). Significant differences (P<0.001) were noted between pancreas: PCR 95% vs CgA 29.2% (P<10(-9)) and small intestine: 100 vs 58% (P<10(-4)). The multigene test was elevated in all grades (G1-G3), in both local and disseminated disease, and was not normalized by somatostatin analog therapy. It was also elevated in 97% of CgA normal NETs. Group 2: PPI administration increased CgA in 83% and CgA was elevated in 26% of controls. PCR values were not elevated in either group. PCR performance metrics were as follows: sensitivity 98.4%, specificity 100%, positive predictive value 100%, negative predictive value 97.8%, and the ROC-derived area under the curve (AUC) was 0.997. These were significantly better than CgA (all metrics <60%; AUC, 0.54; Z-statistic, 10.44, P<0.0001). A 51-panel multigene blood transcript analysis is significantly more sensitive than plasma CgA for NET detection and is unaffected by acid suppression therapy.
神经内分泌肿瘤 (NET) 管理的一个关键要求是使用一种敏感、特异和可重现的血液生物标志物检测。我们评估了一种基于 PCR 的 51 个转录本标志物用于检测肿瘤,将其与嗜铬粒蛋白 A(CgA)进行比较,并研究了质子泵抑制剂(PPIs)的混杂影响,PPIs 会导致 CgA 水平假性升高。该多基因标志物在两组中进行了评估。组 1:前瞻性收集了 125 例 NET 患者:胃肠胰神经内分泌肿瘤(n=91,包括 42 例胰腺和 40 例小肠)、不明原发部位的类癌(n=18)和其他部位(n=16)。组 2:前瞻性收集了接受 PPI 治疗超过 1 个月的非 NET 患者(消化不良,n=19;胃食管反流病,n=6;胰腺炎,n=4)和 50 名对照者。所有样本均通过 PCR(标志物基因)和 ELISA(DAKO-CgA)进行分析。敏感性比较包括卡方检验、非参数测量和接受者操作特征(ROC)曲线。组 1:123 例 NET 患者 PCR 检测呈阳性(98.4%),而 50 例 CgA 检测呈阳性(n=50)(χ(2)=97.3,P<10(-26))。在胰腺(PCR 95% vs CgA 29.2%,P<10(-9))和小肠(100% vs 58%,P<10(-4))中,差异有统计学意义(P<0.001)。多基因检测在所有分级(G1-G3)、局部和播散性疾病中均升高,且不能通过生长抑素类似物治疗来纠正。它也在 97%的 CgA 正常 NET 中升高。组 2:PPI 治疗使 CgA 升高了 83%,而对照者中 CgA 升高了 26%。两组均未升高 PCR 值。PCR 性能指标如下:敏感性 98.4%,特异性 100%,阳性预测值 100%,阴性预测值 97.8%,ROC 衍生曲线下面积(AUC)为 0.997。这些指标均明显优于 CgA(所有指标均<60%;AUC,0.54;Z 统计量,10.44,P<0.0001)。51 个基因 panel 血液转录本分析用于 NET 检测的敏感性明显高于血浆 CgA,且不受酸抑制治疗的影响。